Ovarian Cancer Archive - IOZK

Dendritic cell-based immunotherapy (DCVAC/OvCa) combined with second-line chemotherapy in platinum-sensitive ovarian cancer (SOV02): A randomized, open-label, phase 2 trial

2021-07-20/in Dendritic Cells, International Publications, Ovarian Cancer /von 2021-07-20 / Gynecol Oncol 2021 Sep;162(3):652-660

Th17-inducing autologous dendritic cell vaccination promotes antigen-specific cellular and humoral immunity in ovarian cancer patients

2020-10-14/in Dendritic Cells, International Publications, Ovarian Cancer /von 2020-10-14 / Nat Commun 2020 10;11(1):5173

Advanced clinical trials of dendritic cell vaccines in ovarian cancer

2020-07-27/in Dendritic Cells, International Publications, Ovarian Cancer /von 2020-07-27 / J. Investig. Med. 2020 Jul;

Intranodal Administration of Neoantigen Peptide-loaded Dendritic Cell Vaccine Elicits Epitope-specific T Cell Responses and Clinical Effects in a Patient with Chemorefractory Ovarian Cancer with Malignant Ascites

2020-07-13/in Dendritic Cells, International Publications, Ovarian Cancer /von 2020-07-13 / Immunol. Invest. 2020 Jul;:1-18

Are dendritic cells the most appropriate therapeutic vaccine for patients with ovarian cancer?

2020-04-22/in Dendritic Cells, International Publications, Ovarian Cancer /von 2020-04-22 / Curr. Opin. Biotechnol. 2020 Apr;65:190-196

A Phase I/II trial comparing autologous dendritic cell vaccine pulsed either with personalized peptides (PEP-DC) or with tumor lysate (OC-DC) in patients with advanced high-grade ovarian serous carcinoma

2019-11-26/in Dendritic Cells, International Publications, Ovarian Cancer /von 2019-11-26 / J Transl Med 2019 11;17(1):391

Dendritic Cells Loaded with Heat Shock-Conditioned Ovarian Epithelial Carcinoma Cell Lysates Elicit T Cell-Dependent Antitumor Immune Responses

2019-11-25/in Dendritic Cells, International Publications, Ovarian Cancer /von 2019-11-25 / J Immunol Res 2019;2019:9631515

Phase I/II clinical trial of modulated electro-hyperthermia treatment in patients with relapsed, refractory or progressive heavily treated ovarian cancer

2019-09-01/in Hyperthermia, International Publications, Ovarian Cancer /von 2019-09-01 / Jpn. J. Clin. Oncol. 2019 Sep;49(9):832-838

A phase I trial evaluating the safety and efficacy of weekly paclitaxel or cisplatin with electro-hyperthermia in patients with recurrent or persistent epithelial ovarian, fallopian tubal or primary peritoneal carcinoma (KGOG 3030).

2019-05-31/in Hyperthermia, International Publications, Ovarian Cancer /von 2019-05-31 / J Clin Oncol 37, 2019 (suppl; abstr e17032)

Personalized Dendritic Cell Vaccines-Recent Breakthroughs and Encouraging Clinical Results

2019-04-11/in Dendritic Cells, International Publications, Ovarian Cancer /von 2019-04-11 / Front Immunol 2019;10:766